Avatrombopag Use in Patient With Thromboembolic Risks Listed for Combined Coronary Artery Bypass Grafting and Liver Transplant: A Case Report

Bassem Almalki*, Hersh Shroff, Haripriya Maddur, Juan Caicedo, Clare Kane

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Thrombocytopenia commonly occurs in patients with advanced liver disease and can be a contraindication in patients needing combined coronary artery bypass grafting (CABG) and liver transplant (LT). Thrombopoietin receptor agonists, including avatrombopag, are part of a novel drug class and stimulate platelet production. Avatrombopag is indicated in the perioperative setting to avoid platelet transfusions, which carry several disadvantages. Avatrombopag was shown to be safe and effective in patients with chronic liver disease. This study describes the successful use of avatrombopag in a patient with thromboembolic risks in preparation for a combined CABG and LT. Larger clinical trials are necessary to validate our results.

Original languageEnglish (US)
Pages (from-to)2567-2569
Number of pages3
JournalTransplantation proceedings
Volume53
Issue number8
DOIs
StatePublished - Oct 2021

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Fingerprint

Dive into the research topics of 'Avatrombopag Use in Patient With Thromboembolic Risks Listed for Combined Coronary Artery Bypass Grafting and Liver Transplant: A Case Report'. Together they form a unique fingerprint.

Cite this